Neuphoria Therapeutics (NEUP) to Release Earnings on Friday

Neuphoria Therapeutics (NASDAQ:NEUP) is expected to announce its results before the market opens on Friday, February 13th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.

Neuphoria Therapeutics (NASDAQ:NEUP) last issued its earnings results on Friday, November 14th. The company reported ($4.41) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($3.86). On average, analysts expect Neuphoria Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Neuphoria Therapeutics Price Performance

NEUP opened at $3.99 on Friday. Neuphoria Therapeutics has a 12 month low of $3.64 and a 12 month high of $21.40. The business has a 50 day simple moving average of $4.04 and a 200-day simple moving average of $7.48. The stock has a market capitalization of $21.47 million, a P/E ratio of -0.82 and a beta of 0.52.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Neuphoria Therapeutics stock. Millennium Management LLC acquired a new position in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,329 shares of the company’s stock, valued at approximately $216,000. Millennium Management LLC owned 0.78% of Neuphoria Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NEUP has been the subject of a number of research analyst reports. HC Wainwright dropped their target price on shares of Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating for the company in a report on Friday, December 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday, January 22nd. Zacks Research raised Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Finally, Wall Street Zen lowered Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 23rd. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Neuphoria Therapeutics has a consensus rating of “Hold” and a consensus target price of $21.00.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.